Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
- Published: December 2010
The expanding diabetes market is opening up new and lucrative opportunities for companies with innovative technologies and experimental candidates. The launch of novel agents and a steady increase in the drug-treated patient population are fueling growth in this market. The R&D pipeline includes drugs against the promising novel targets SGLT, PTP1B, 11ß-HSD1, and others; clinical trials testing disease-modifying agents for type 1 diabetes are also under way.
Questions answered in this report:
- Type 2 diabetes is a significant public health threat and an important and growing pharmaceutical market; type 1 diabetes also continues to suffer from significant unmet needs. How large is the current market for type 1 and type 2 diabetes? How much will this market grow over the next ten years? What factors will drive this market growth?
- Unmet needs in type 2 diabetes have led to a flurry of R&D activity and a dense development pipeline. What novel diabetes targets hold the most promise for drug discovery and development? Which new treatment strategies are being pursued, and which are the most advanced?
- The need for disease-modifying therapies, especially for type 1 diabetes, has prompted the clinical development of several novel technologies. What novel approaches are in clinical development for type 1 diabetes? Which companies are leading the development of these programs?
- The current market landscape offers significant commercial opportunity to innovative biotech companies with novel development programs. Which biotech companies have developed innovative approaches to drug discovery and development? How far have these programs advanced?
- Pharmaceutical companies can refuel pipelines and access new technologies through partnerships and M&As. Which pharmaceutical companies have formed major alliances with biotech companies? Which therapeutic strategies are drawing the interest of Big Pharma?
- Eli Lilly and Boehringer Ingelheim formed a high-value deal in January 2011 for the development of new diabetes therapies. What are the key features of this deal? How does this collaboration address each partner’s strategic interests? How does this deal reflect trends in diabetes partnering activity?
Scope of the report:
- Introduction to the diabetes market: Market size, market growth, market drivers, product sales, unmet needs.
- Disease and therapy: Disease etiology and pathophysiology, current therapies, mechanisms of action, DPP-IV inhibitors, GLP-1 analogues, PPAR-g agonists.
- Primary data: Survey of 50 U.S. endocrinologists and 50 U.S. primary care physicians ranking the top unmet needs in diabetes.
- Novel targets for type 2 diabetes: Mechanisms of action, novel targets and approaches, compounds in development, companies, and partnerships.
- Novel approaches to insulin delivery and disease modification: Inhaled insulin, buccal delivery, anti-CD3 MAbs, immunotherapies, preservation of beta-cell mass and function, vaccines, islet-cell neogenesis.
- Dealmaking activity: Corporate partnerships, M&As, innovative biotech companies. SHOW LESS READ MORE >
- Strategic Considerations
- Stakeholder Implications
Introduction to the Diabetes Market
Type 1 Diabetes
- Disease Overview
- Current Therapies
Type 2 Diabetes
- Disease Overview
- Insulin Resistance
- Defects in Insulin Secretion
- Excess Hepatic Glucose Production
- Current Therapies
Key Novel Drug Targets for Type 2 Diabetes
- Sodium-Dependent Glucose Cotransporter Inhibitors
- Protein Tyrosine Phosphatase 1B Inhibitors
- 11ß-Hydroxysteroid Dehydrogenase Inhibitors
- Centrally Acting Drugs
- Inhibitors of Inflammation
- Glucokinase Activators
- Diacylglycerol Acetyl Transferase Inhibitors
- G-Protein-Coupled Receptor 119 Agonists
- G-Protein-Coupled Receptor 40 Agonists
- Sirtuin Activators
Novel Approaches to Insulin Delivery
- Inhaled Insulin
- Buccal Delivery
Spectrum Expert Commentary: The Opportunity for Inhaled Insulin
Emerging Immunomodulatory Mechanisms for Type 1 Diabetes
- Anti-CD Monoclonal Antibodies
Strategic Partnering in Diabetes: Innovation in R&D
Outlook for Novel Approaches to Treating Type 1 and Type 2 Diabetes
About the Author
- Alantos Pharmaceuticals
- Alizé Pharma
- Amylin Pharmaceuticals
- Anchor Therapeutics
- Andromeda Biotech
- Arena Pharmaceuticals
- Array Biopharma
- Ascendis Pharma
- Bayhill Therapeutics
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cellartis/Lund University
- Cengent Therapeutics
- Chiesi Farmaceutici
- Clal Biotechnology Industries
- Dainippon Sumitomo
- Diamyd Medical
- Daiichi Sankyo
- Eli Lilly
- Envoy Therapeutics
- Forest Laboratories
- Generex Biotechnology
- Glenmark Pharmaceuticals
- Human Genome Sciences
- Inhale Therapeutic Systems (now Nektar Therapeutics)
- Isis Pharmaceuticals
- Johnson & Johnson/Mitsubishi Tanabe
- Juvenile Diabetes Research Foundation
- Kissei Pharmaceutical
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- Marcadia Biotech
- Merck KGaA
- Merrion Pharmaceuticals
- Metabasis Therapeutics
- Nektar Therapeutics (formerly Inhale Therapeutic Systems)
- Neurocrine Biosciences
- Novo Nordisk
- Ono Pharmaceutical
- Ortho-McNeil Pharmaceutical
- OSI Pharmaceuticals
- Palatin Technologies
- PDL Biopharma
- Rhythm Pharmaceuticals
- Sirtris Pharmaceuticals
- Swedish Orphan Biovitrum
- Taisho Pharmaceuticals
- Transition Therapeutics
- TransTech Pharma
- Vitae Pharmaceuticals
- Wellstat Therapeutics
- Yissum Research Development of Hebrew University
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|Enterprisewide||The report will be emailed to you. The report is sent in PDF format.||This is an enterprise license, allowing all employees within your organisation access to the product.|